Are Mock Pre-Submission Meetings Worth the Investment in FDA Preparation?

Understanding the Concept of Mock Pre-Submission Meetings

A mock pre-submission meeting is a simulated regulatory interaction where a sponsor team rehearses the format, flow, and content of an actual FDA meeting (Type A, B, or C). These rehearsals are typically conducted before engaging with the FDA to build internal alignment, test messaging, and identify gaps in preparation. While not mandated by regulatory authorities, mock meetings have become a best practice among top-tier pharmaceutical, biotech, and medical device companies.

In a high-stakes environment where each agency meeting could significantly alter development timelines or trial design, simulating the regulatory discussion allows teams to pressure-test their strategies in a low-risk setting.

Core Objectives of a Mock FDA Meeting

• Familiarize Stakeholders: Expose team members to the structure and expectations of an FDA meeting.
• Identify Weaknesses: Detect vague questions, unclear messaging, or incomplete data presentation in the briefing package.
• Train the Spokesperson: Prepare the designated speaker or regulatory lead for smooth delivery and controlled discussions.
• Stress-Test Responses: Use “challenger” roles to simulate potential FDA pushback or difficult questions.
• Refine Team Coordination: Ensure functions (Regulatory, Clinical, CMC, Nonclinical) are aligned and not contradicting each other.

A well-executed mock meeting minimizes surprises during the real interaction and helps avoid common pitfalls.

When Should You Conduct a Mock Meeting?

Ideally, mock meetings should occur after finalizing the draft briefing document but before its submission to the FDA (typically 30 days prior to the scheduled meeting). This timing allows sufficient room for content revision and team retraining, if necessary.

For example, if an FDA Type B meeting is scheduled for October 15, and the submission deadline is September 15, the mock meeting should occur around September 5–10 to accommodate feedback integration.

Continue with Structure, Case Studies, Templates, and Global Best Practices

Structure of an Effective Mock Meeting

A successful mock pre-submission meeting replicates the real FDA format as closely as possible. Here’s a typical agenda:

• Opening Remarks: Regulatory lead introduces objectives and participants
• Agenda Review: Walkthrough of topics mirroring the briefing document
• Presentation Simulation: Functional leads present data summaries
• Mock Q&A: Internal “FDA panel” poses challenging questions
• Debrief and Feedback: Evaluation of performance, timing, and message clarity

Some companies even engage external consultants or ex-regulators to play the FDA role for realism.

Case Study: Impact of a Mock Meeting on Development Strategy

A mid-sized sponsor preparing for a Type C meeting on a rare disease biologic decided to simulate their FDA interaction. During the mock session, the internal “reviewer” challenged their endpoint justification and raised concerns about insufficient pediatric data.

The feedback led to:

• Rephrasing key clinical questions for better clarity
• Including supplementary PK data in the briefing book
• Designating a single clinical spokesperson for focus

As a result, the FDA meeting went smoothly, and the agency agreed to the proposed pivotal trial design—saving the sponsor 6 months in rework.

Templates and Tools Used in Mock Meeting Planning

• Briefing Book Draft: Shared in editable format for real-time markups
• Mock Meeting Script: Includes opening remarks, speaker notes, and Q&A rotation
• Performance Checklist: Tracks timing, clarity, regulatory accuracy, and alignment
• Debrief Form: Captures reviewer feedback by agenda topic

Using such structured templates ensures all stakeholders know what to expect and how to prepare.

Role of Regulatory Affairs in Mock Meeting Execution

Regulatory Affairs (RA) leads the mock meeting initiative. Their responsibilities include:

• Scheduling and inviting all functional stakeholders
• Assigning FDA panel roles internally or externally
• Facilitating rehearsals and managing time
• Incorporating mock feedback into the final submission

RA also ensures alignment with FDA expectations based on prior guidance and regulatory precedents.

Global Best Practices: Mock Meetings Beyond the FDA

Regulatory agencies worldwide encourage pre-submission consultation. Sponsors preparing for EMA’s Scientific Advice or PMDA pre-consultation meetings often adopt similar mock formats. Some organizations even standardize mock rehearsal procedures globally to ensure consistency.

To explore agency-specific formats, visit the Australia New Zealand Clinical Trials Registry (ANZCTR), which offers region-specific regulatory engagement timelines and expectations.

Conclusion: A Small Investment for a Significant Return

While not mandatory, mock pre-submission meetings are invaluable tools for sponsors seeking confident, aligned, and efficient regulatory engagements. They reduce risk, sharpen communication, and prepare teams for any curveballs from the FDA.

For organizations with high regulatory stakes or novel products, skipping the mock process may be more expensive in the long run. A 2-hour simulation today could prevent a 6-month delay tomorrow.